Model‐informed precision dosing of carboplatin in cancer patients by leveraging myelosuppression data from electronic health records
The pop-PK-PD model demonstrated strong performance in describing and predicting carboplatin-induced myelosuppression, thus providing a valuable strategy for dose personalization. Further refinements and validation steps are needed before integrating such an approach into clinical workflows.
Authors
- Jan Buter (ORCID: https://orcid.org/0000-0002-2929-1070)
- Medhat M. Said (ORCID: https://orcid.org/0000-0001-7954-6580)
- Alessandro De Carlo (ORCID: https://orcid.org/0000-0001-7055-2140)
- Harmen Huls
- Lia van Zuijlen
- Tim Schutte (ORCID: https://orcid.org/0000-0002-4096-0917)
- Elena M. Tosca (ORCID: https://orcid.org/0000-0002-9801-2135)
- Idris Bahce (ORCID: https://orcid.org/0000-0002-1111-608X)
- Paolo Magni (ORCID: https://orcid.org/0000-0002-8931-4676)
- Mirjam Crul
- Imke H. Bartelink (ORCID: https://orcid.org/0000-0001-9602-3407)
Institutions
- University of Pavia (IT)
- The Netherlands Cancer Institute (NL)
- Oncode Institute (NL)
- Vrije Universiteit Amsterdam (NL)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2025-12-22
- DOI
- https://doi.org/10.1002/bcp.70413
- Primary Topic
- Neutropenia and Cancer Infections
- Type
- article
- Field-Weighted Citation Impact
- 0.00